Summary - Funding Rounds

Founding Date

1986
Shire is a subsidiary of Takeda Pharmaceutical

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 26.2% from Hematology, 10.0% from Genetic Diseases, 18.4% from Neuroscience, 30.2% from Immunology, 11.6% from Internal Medicine and 3.6% from Other

Shire Income Statement

Annual

GBPFY, 2016FY, 2017FY, 2018

Revenue

11.4b15.2b43.0m

Revenue growth, %

70%33%

Operating expense total

46.4m5.3b

Depreciation and amortization

1.2b1.8b9.0k

EBITDA

1.8m

EBITDA margin, %

0%

EBIT

1.1m2.5b

EBIT margin, %

0%16%

Interest expense

39.0k

Interest income

2.2m

Pre tax profit

2.4m6.3m3.8m

Income tax expense

(28.0k)3.2m376.0k

Net Income

2.5m3.1m3.4m

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q2, 2018Q3, 2018

Revenue

816.2m849.4m874.3m972.2m1.1b1.1b1.2b1.2b1.1b1.2b1.3b1.2b1.3b1.5b1.7b1.7b2.4b3.7b3.9b3.9b

Cost of goods sold

101.9m119.1m112.7m124.5m143.7m166.5m158.4m152.5m167.9m155.9m175.7m197.1m229.5m227.8m248.6m778.1m1.3b1.1b1.1b1.2b

Gross profit

714.3m730.3m761.6m847.7m919.2m919.6m1.0b1.1b932.5m1.0b1.1b1.0b1.1b1.3b1.5b1.7b2.6b2.8b2.7b

Gross profit Margin, %

88%86%87%87%86%85%86%87%85%87%86%84%83%85%85%68%70%72%70%

R&D expense

131.0m147.0m197.9m177.9m176.9m201.5m220.3m238.6m224.7m224.2m260.1m229.1m360.5m193.7m217.1m294.8m542.4m427.6m407.2m

General and administrative expense

359.9m354.4m392.4m402.9m440.3m452.1m500.0m511.0m437.4m438.7m457.6m441.1m430.3m506.6m575.0m609.5m675.3m899.1m907.7m836.8m

Operating expense total

496.5m505.9m605.8m581.2m635.9m664.2m718.4m753.1m659.1m876.9m757.0m698.7m810.4m700.3m575.0m1.2b970.1m3.9b1.4b2.0b1.8b

Depreciation and amortization

213.0m354.9m364.0m434.1m

EBIT

217.8m224.4m155.8m266.5m283.3m255.4m295.0m302.2m273.4m129.1m341.8m340.8m306.9m474.6m455.8m543.9m96.2m(405.9m)497.1m399.2m830.2m955.8m

EBIT margin, %

27%26%18%27%27%24%25%25%25%11%27%28%23%32%28%32%4%11%21%25%

Interest expense

700.0k10.4m6.5m9.2m9.9m9.7m10.2m9.6m9.2m9.1m8.9m8.0m2.6m9.6m87.2m141.3m96.0m220.0m

Interest income

2.0m1.0m1.6m1.1m

Investment income

(500.0k)1.0m(300.0k)1.2m1.2m800.0k900.0k(600.0k)200.0k400.0k500.0k(300.0k)(600.0k)5.7m4.7m

Pre tax profit

220.0m214.0m149.3m258.2m274.0m261.6m287.5m291.4m268.6m119.6m332.0m332.8m304.3m471.3m455.5m491.7m16.6m(597.2m)362.4m261.5m734.2m735.8m

Income tax expense

53.6m54.5m52.7m48.1m69.7m69.5m50.0m53.0m41.6m55.2m74.4m54.3m50.6m57.4m82.1m70.9m24.3m124.4m203.3m

Net Income

165.9m160.5m96.3m211.3m205.5m192.9m238.4m237.8m227.2m64.8m258.1m278.2m230.4m410.4m419.0m(162.1m)(386.8m)375.0m240.3m615.5m537.2m

Shire Balance Sheet

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

45.7k219.3k17.0k4.0k550.6m620.0m1.5b2.2b3.0b135.5m528.8m472.4m

Accounts Receivable

5.0k4.0k692.5m845.0m824.2m961.2m1.2b2.6b3.0b

Prepaid Expenses

45.1m174.9m221.8m263.0m221.5m197.4m806.3m795.3m

Inventories

260.0m340.1m436.9m455.3m544.8m635.4m3.6b3.3b

Current Assets

6.1m7.4m22.4m16.0m21.0m41.2m21.4m5.9m7.4m72.4m51.1m75.3m116.7m143.6m1.9b2.2b3.2b4.3b5.2b2.3b7.5b7.6b18.8m

PP&E

205.5k188.0k432.0k507.0k12.1m12.3m12.7m20.7m19.5m21.3m23.3m22.9m26.9m38.8m853.4m932.1m955.8m891.8m837.5m828.1m6.5b6.6b

Goodwill

402.5m592.6m644.5m624.6m2.5b4.1b17.9b19.8b

Total Assets

6.4m7.6m22.8m16.5m33.1m53.5m34.1m26.6m26.9m273.3m158.9m151.2m170.4m182.9m5.4b6.4b7.3b8.3b13.6b16.6b67.0b67.8b190.3m

Accounts Payable

398.1k533.1k486.0k1.0m2.0m594.0k673.0k88.0k1.3m1.9m730.0k356.0k2.9m295.0k1.2b1.4b1.5b1.7b1.9b2.1b4.3b4.2b612.0k

Short-term debt

860.7m1.1b1.1b3.1b2.8b6.3m

Current Liabilities

1.5m4.6m15.9m10.3m27.1m59.2m49.6m57.2m67.9m81.1m32.1m14.4m15.7m18.3m1.3b2.5b1.6b1.8b3.0b3.7b7.7b7.9b8.7m

Long-term debt

1.1b1.1b69.9m19.9b

Non-Current Liabilities

227.5m226.7m227.2m3.6m6.6m30.3b28.0k

Total Debt

278.0k1.2m2.9m4.8m4.9m2.9m540.0k56.0k124.0k1.1b860.7m2.2b1.6b19.9b19.5b6.3m

Total Liabilities

1.5m4.6m15.9m10.3m27.1m59.2m49.6m57.2m67.9m308.6m258.8m241.6m19.3m24.9m2.9b3.2b3.5b3.0b5.0b6.8b38.1b31.6b8.8m

Common Stock

55.7m55.7m55.7m58.6m58.7m58.9m81.3m81.6m230.6m

Additional Paid-in Capital

6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m6.1m230.6m230.6m2.7b2.9b3.0b4.2b4.3b4.5b24.7b25.1b

Retained Earnings

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(160.3m)502.9m995.5m1.5b4.6b5.8b5.9b9.9b(34.1m)

Total Equity

4.9m3.0m6.9m6.2m6.0m(5.7m)(15.5m)(30.5m)(41.1m)(35.3m)(99.9m)(90.4m)151.1m157.9m2.5b3.2b3.8b5.4b8.7b9.8b28.9b36.2b181.5m

Debt to Equity Ratio

0.1 x0.2 x0.5 x0.8 x-0.9 x-0.2 x0 x0 x0 x0.4 x0.3 x0.6 x0.2 x0.7 x0.5 x0 x

Debt to Assets Ratio

0 x0.1 x0.2 x0.1 x0.1 x0.1 x0 x0 x0 x0.2 x0.1 x0.3 x0.1 x0.3 x0.3 x0 x

Financial Leverage

1.3 x2.5 x3.3 x2.7 x5.5 x-9.4 x-2.2 x-0.9 x-0.7 x-7.7 x-1.6 x-1.7 x1.1 x1.2 x2.2 x2 x1.9 x1.6 x1.6 x1.7 x2.3 x1.9 x1 x

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

657.5m682.5m193.3m712.0m144.6m276.4m879.4m1.1b1.3b1.5b1.3b1.7b139.1m153.6m467.7m74.3m64.0m44.9m69.0m693.4m728.6m369.0m263.7m209.3m317.7m259.7m193.2m

Accounts Receivable

620.7m612.5m722.1m786.3m797.2m844.7m921.2m815.4m863.6m884.4m915.2m1.0b1.1b1.1b1.1b1.1b1.1b1.3b1.3b2.4b2.6b2.6b2.8b2.8b3.1b3.0b3.2b

Prepaid Expenses

37.8m41.4m44.8m41.9m57.4m148.3m135.1m143.5m283.2m289.1m282.3m350.3m418.6m402.4m216.6m221.6m215.0m314.4m733.6m665.3m787.2m778.5m779.9m1.1b3.1b900.1m

Inventories

215.6m232.7m252.6m281.9m336.3m325.9m368.7m411.8m427.5m471.4m492.2m480.5m636.2m585.0m548.9m588.7m632.8m608.9m680.0m5.8b4.9b3.3b3.3b3.4b3.3b3.4b3.5b

Current Assets

1.8b1.9b2.2b2.1b1.7b1.8b2.6b2.7b3.0b3.3b3.2b3.7b2.6b2.6b2.9b2.5b2.5b2.7b2.4b9.7b8.9b7.1b7.2b7.3b7.9b9.8b7.8b

PP&E

668.5m801.1m818.6m869.8m905.8m918.8m921.8m925.7m931.9m951.0m953.1m965.1m884.0m852.5m845.6m821.9m816.7m795.9m837.6m6.6b6.5b6.5b6.6b6.6b6.5b6.4b6.5b

Goodwill

373.2m355.7m375.0m414.9m612.9m596.2m598.8m636.0m639.2m522.8m611.6m621.3m2.2b2.3b2.4b4.2b4.2b6.9b13.0b14.9b19.1b19.5b19.7b20.0b19.0b19.1b

Total Assets

4.7b4.9b5.1b5.7b6.2b6.1b6.7b7.0b7.3b7.6b7.9b8.4b10.9b11.3b11.5b17.7b17.0b17.5b24.1b70.7b69.8b66.2b67.2b67.5b67.9b66.2b63.8b

Accounts Payable

929.2m1.0b1.1b1.2b1.3b1.3b1.4b1.4b1.4b1.5b1.5b1.6b1.8b1.8b1.7b2.0b1.9b2.0b2.0b3.7b4.0b3.6b3.8b3.9b3.9b3.9b4.0b

Short-term debt

634.3m664.2m1.1b1.1b1.1b1.1b1.1b1.1b1.1b1.1b2.7b2.7b3.0b3.2b2.6b1.8b1.2b4.2b

Current Liabilities

969.0m1.1b1.2b1.2b2.5b2.5b1.4b1.5b1.5b1.6b2.7b2.8b2.5b2.2b2.0b4.9b4.3b4.3b4.3b6.9b7.1b7.0b7.4b7.5b6.9b6.3b8.5b

Long-term debt

1.1b6.8m6.8m1.1b1.1b1.1b1.1b1.1b850.0m850.0m850.0m78.7m73.9m70.7m4.7b21.3b21.0b19.5b18.4b18.0b16.7b16.7b11.1b

Total Debt

1.1b641.1m671.0m1.1b1.1b1.1b2.2b2.2b2.2b2.2b1.1b1.1b850.0m850.0m850.0m2.6b2.3b2.1b6.9b24.0b23.7b22.5b21.6b20.6b18.5b17.9b15.3b

Total Liabilities

2.7b2.8b2.8b2.9b3.3b3.1b3.2b3.4b3.4b3.8b4.1b4.2b5.3b5.2b5.0b8.7b7.9b7.9b13.8b41.0b40.0b36.4b35.9b34.8b30.5b29.5b26.5b

Common Stock

55.6m55.7m55.7m55.7m55.7m55.7m55.7m55.7m55.7m55.7m55.8m55.8m58.6m58.6m58.7m58.9m58.9m58.9m59.0m81.0m81.3m81.4m81.5m81.5m81.7m81.9m81.9m

Additional Paid-in Capital

2.7b2.7b2.7b2.8b2.8b2.8b2.9b2.9b3.0b3.0b3.0b3.0b4.2b4.3b4.3b4.4b4.4b4.4b4.5b24.5b24.6b24.9b25.0b25.0b25.2b25.3b25.4b

Retained Earnings

(492.0m)(386.0m)(299.4m)(7.7m)109.4m279.1m614.7m768.7m981.8m1.0b1.2b1.4b1.6b2.0b2.5b5.0b5.1b5.5b6.2b5.9b5.5b6.3b6.3b6.9b10.6b10.9b11.5b

Total Equity

2.1b2.1b2.3b2.8b2.9b3.0b3.5b3.6b3.9b3.8b3.8b4.2b5.6b6.1b6.5b9.0b9.1b9.6b10.3b29.8b29.8b29.7b31.3b32.7b37.4b36.8b37.3b

Debt to Equity Ratio

0.6 x0.3 x0.3 x0.4 x0.4 x0.4 x0.6 x0.6 x0.6 x0.6 x0.3 x0.3 x0.2 x0.1 x0.1 x0.3 x0.3 x0.2 x0.7 x0.8 x0.8 x0.8 x0.7 x0.6 x0.5 x0.5 x0.4 x

Debt to Assets Ratio

0.2 x0.1 x0.1 x0.2 x0.2 x0.2 x0.3 x0.3 x0.3 x0.3 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.2 x

Financial Leverage

2.3 x2.3 x2.2 x2 x2.1 x2.1 x1.9 x1.9 x1.9 x2 x2.1 x2 x1.9 x1.9 x1.8 x2 x1.9 x1.8 x2.3 x2.4 x2.3 x2.2 x2.1 x2.1 x1.8 x1.8 x1.7 x

Shire Cash Flow

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m588.0m865.0m745.4m665.1m3.4b1.3b327.4m4.3b

Depreciation and Amortization

255.5m294.8m308.6m324.4m407.3m637.2m1.5b2.3b

Accounts Receivable

(114.4m)(134.0m)22.2m(148.3m)(66.1m)(211.4m)(701.7m)(487.6m)

Inventories

(58.2m)(64.4m)(88.2m)(36.6m)(25.3m)(63.2m)(255.8m)(145.1m)

Accounts Payable

25.9m(10.0m)136.7m67.9m5.3m109.2m621.6m

Cash From Operating Activities

954.9m1.1b1.4b1.5b4.2b2.3b2.7b4.3b

Purchases of PP&E

(449.6m)(725.0m)(97.0m)(227.8m)(5.6b)(17.5b)

Capital Expenditures

(326.6m)(194.3m)(149.6m)(157.0m)(77.0m)(114.7m)

Cash From Investing Activities

(797.4m)(809.2m)(271.0m)(360.9m)(4.0b)(5.6b)(18.1b)(700.9m)

Short-term Borrowings

(30.0m)(1.5b)(3.1b)(16.4b)(7.7b)

Long-term Borrowings

(2.4m)(1.5m)

Dividends Paid

(62.0m)(73.8m)(86.3m)(96.4m)(121.2m)(134.4m)(171.3m)(281.3m)

Cash From Financing Activities

(99.5m)(195.4m)(244.3m)(344.6m)554.5m439.0m15.8b(3.6b)

Net Change in Cash

51.7m69.4m862.2m757.2m743.0m(2.8b)393.3m(56.4m)

Interest Paid

25.9m33.3m34.6m554.2m

Income Taxes Paid

329.2m286.1m199.2m

Free Cash Flow

628.3m879.3m1.2b1.3b4.2b2.2b

Quarterly

USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

165.9m326.2m422.7m211.3m416.8m609.7m238.4m476.2m703.4m64.8m322.9m601.1m230.4m753.5m1.2b410.4m570.0m1.0b419.0m(129.9m)375.0m615.3m1.2b550.6m1.2b1.7b

Depreciation and Amortization

64.3m129.1m189.2m63.5m132.3m212.3m73.0m152.4m231.5m75.0m151.2m229.4m96.5m204.8m307.1m120.6m291.8m457.4m168.9m429.8m877.8m486.9m1.0b1.6b624.2m1.2b1.8b

Accounts Receivable

(10.8m)(43.9m)(138.0m)(74.8m)(56.2m)(122.8m)(65.2m)22.4m(23.0m)(51.3m)(102.6m)(215.2m)(77.3m)(37.3m)(92.1m)(85.1m)(84.9m)(288.1m)(100.9m)(181.0m)(411.2m)(35.3m)(181.5m)(301.5m)(291.7m)(126.3m)(362.0m)

Inventories

(24.2m)(50.1m)(54.1m)(12.7m)(30.6m)(42.8m)(25.0m)(67.0m)(81.9m)(29.1m)(53.9m)(39.9m)(18.6m)(11.7m)(15.8m)(22.0m)(37.4m)(21.7m)(32.2m)(116.4m)(228.0m)(151.8m)(171.6m)(245.2m)(40.2m)(169.8m)(305.4m)

Accounts Payable

(116.1m)(43.2m)(41.0m)(72.8m)(77.1m)(101.4m)(30.3m)34.7m72.7m(93.5m)(160.7m)(71.4m)(145.5m)(145.1m)(92.8m)77.5m(39.8m)56.5m(154.6m)342.7m315.2m(671.5m)(445.1m)(557.8m)(172.6m)(186.3m)(244.8m)

Cash From Operating Activities

186.2m469.9m612.0m201.9m485.5m664.2m257.0m722.8m1.0b160.4m419.0m852.7m246.1m1.1b1.7b561.6m1.0b1.6b389.5m980.4m1.5b459.1m1.7b2.7b1.0b1.9b2.8b

Purchases of PP&E

(719.7m)(723.5m)(97.0m)(97.0m)(77.2m)(227.8m)(227.8m)(3.8b)(4.0b)(5.2b)(5.2b)(5.6b)(5.7b)(17.5b)(17.5b)(564.6m)

Capital Expenditures

(43.6m)(208.1m)(261.7m)(46.5m)(95.0m)(135.9m)(31.7m)(64.4m)(91.6m)(47.3m)(65.0m)(110.3m)(19.1m)(49.8m)(39.8m)(62.1m)

Cash From Investing Activities

(35.2m)(202.7m)(831.5m)(51.9m)(805.9m)(762.0m)(34.2m)(179.9m)(215.6m)(121.3m)(279.3m)(321.0m)(3.7b)(3.9b)(4.0b)(5.2b)(5.2b)(5.6b)(5.7b)(17.6b)(17.8b)(219.8m)(355.9m)(491.2m)(188.9m)(396.9m)1.7b

Short-term Borrowings

(13.1m)(30.0m)(3.0m)(650.2m)(1.3b)(1.5b)(1.5b)(2.5b)(995.1m)(1.5b)(14.6b)(1.8b)(3.5b)(5.7b)(1.4b)(4.3b)(8.0b)

Long-term Borrowings

(700.0k)(1.3m)(1.8m)(200.0k)(400.0k)(1.0m)(300.0k)

Dividends Paid

(49.8m)(49.8m)(60.5m)(60.5m)(70.7m)(70.7m)(79.2m)(79.2m)(99.6m)(99.6m)(110.2m)(110.2m)(130.2m)(130.2m)(234.7m)(234.7m)(276.6m)(276.6m)

Cash From Financing Activities

5.6m(89.7m)(84.7m)9.0m(88.3m)(176.8m)35.4m(48.6m)(88.6m)(72.9m)(317.1m)(327.3m)1.3b773.3m567.2m1.7b1.3b1.1b5.2b17.2b16.9b(401.8m)(1.6b)(2.6b)(982.1m)(1.8b)(4.8b)

Net Change in Cash

158.6m183.6m(305.6m)161.4m(406.0m)(274.2m)259.4m492.7m701.9m(31.5m)(180.3m)203.9m(2.1b)(2.1b)(1.8b)(2.9b)(2.9b)(2.9b)(66.5m)557.9m593.1m(159.8m)(265.1m)(319.5m)(158.6m)(217.1m)(278.7m)

Interest Paid

(700.0k)13.0m11.7m500.0k16.2m16.9m1.1m17.3m18.6m1.0m16.9m7.7m223.4m108.2m267.0m434.9m152.5m242.4m427.1m

Income Taxes Paid

(89.7m)205.0m291.6m6.4m147.7m264.5m29.5m68.3m134.6m96.1m196.8m65.2m355.8m23.1m176.0m308.0m45.0m424.5m528.4m

Free Cash Flow

142.6m261.8m350.3m155.4m390.5m528.3m225.3m658.4m919.6m113.1m354.0m742.4m1.1b1.6b974.1m1.5b

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Approved Phase Products

2 3 4 7

Projects in R&D Pipeline

27 29 37 40

Countries

68 72 100 100

Preclinical Phase Products

33 33 35 35

Franchises

7

Manufacturing Sites

14

New Product Launches

50

Products Marketed

40

Shire Human Capital

Gender

FY, 2016FY, 2015
Male, percent48 %50 %
Female, percent52 %50 %

Shire Employee Rating

3.01132 votes
Culture & Values
2.8
Work/Life Balance
3.2
Senior Management
2.5
Salary & Benefits
3.7
Career Opportunities
2.9
Source